{"id":177061,"date":"2026-01-21T19:13:41","date_gmt":"2026-01-22T00:13:41","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=177061"},"modified":"2026-01-22T19:22:05","modified_gmt":"2026-01-23T00:22:05","slug":"dr-reddys-laboratories-reports-q3-fy-26-revenue-rise-14-profit-drop-on-pricing-pressures","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-reports-q3-fy-26-revenue-rise-14-profit-drop-on-pricing-pressures\/","title":{"rendered":"Dr. Reddy\u2019s Laboratories Reports Q3 FY ’26 Revenue Rise, 14% Profit Drop on Pricing Pressures"},"content":{"rendered":"\n

Dr. Reddy\u2019s Laboratories Ltd. (NSE: DRREDDY), the Indian drugmaker, on Wednesday reported a modest rise in third-quarter revenue but a notable decline in net profit as pressure from pricing and product-specific challenges weighed on earnings for the quarter ended Dec. 31, 2025.\u00a0<\/p>\n\n\n\n

Revenue Growth Moderates; Profit Falls<\/strong><\/h2>\n\n\n\n

Consolidated revenue increased 4.4% year-on-year to \u20b98,726.8 crore ($971 million) in the third quarter of fiscal 2026, driven by broad-based growth across certain overseas markets and domestic businesses. The top line narrowly beat expectations, reflecting resilience in branded and emerging market segments. <\/p>\n\n\n\n

However, net profit attributable to equity holders declined about 14% from a year earlier to \u20b91,209.8 crore, compared with \u20b91,413.3 crore in the corresponding quarter of the previous fiscal year. Earnings were also lower sequentially, highlighting mounting headwinds in key markets. <\/p>\n\n\n\n

Margins Under Strain<\/strong><\/h2>\n\n\n\n

On the operating front, EBITDA fell nearly 11% to \u20b92,049.3 crore, with the EBITDA margin contracting to 23.5% from 27.5% in the year-ago period. The company said profitability was affected by pricing pressures in its North American generics business and a one-time provision related to new labour code compliance in India, which added to costs during the quarter. Excluding that provision, adjusted margins would have been moderately higher. <\/p>\n\n\n\n

Gross margin for the quarter eased to 53.6% from 58.7% a year ago, as cost pressures and erosion in certain high-margin products persisted. Selling, general and administrative (SG&A) expenses rose, reflecting investment in commercial operations and strategic initiatives. Research and development (R&D) expenditure amounted to about 7% of revenues, underpinning ongoing investment in new product development. <\/p>\n\n\n\n

Market Performance and Product Mix<\/strong><\/h2>\n\n\n\n

Dr. Reddy\u2019s said growth in the quarter was supported by robust performance in Europe, India and emerging markets, which recorded double-digit increases, partially offsetting weakness in the company\u2019s largest revenue contributor, North America Generics. Revenue from the North American generics segment declined year-on-year, largely due to lower sales of lenalidomide and other key products, while other regional markets delivered stronger results. <\/p>\n\n\n\n

In the global generics business overall, revenues were up about 7% on a year-on-year basis. The Pharmaceutical Services and Active Ingredients (PSAI) segment saw a slight decline in sales, reflecting continued volatility in API markets. <\/p>\n\n\n\n

Cash Flow and Balance Sheet Dynamics<\/strong><\/h2>\n\n\n\n

Despite margin pressures, the company\u2019s cash flow position remained solid, with a reported net cash surplus of approximately \u20b93,069 crore ($342 million) at the end of the quarter. Operating working capital increased as inventories and receivables rose modestly, and capital expenditure continued in line with strategic capacity expansions. Free cash flow generation was positive, albeit moderated by investment activity and working capital changes. <\/p>\n\n\n\n

Management Commentary and Strategic Priorities<\/strong><\/h2>\n\n\n\n

Management highlighted ongoing efforts to expand the company\u2019s base business, accelerate its development pipeline and pursue operational efficiencies. \u201cWe continue to focus on disciplined execution of our strategic priorities of base business growth, pipeline advancement, operational efficiencies, and select inorganic opportunities to create long-term value for our stakeholders,\u201d Co-Chairman and Managing Director, G. V. Prasad said in a statement. <\/p>\n\n\n\n

Dr. Reddy\u2019s noted continued progress on product launches and regulatory filings across markets, including biosimilars and complex generics, although competitive dynamics in mature markets like the U.S. continued to challenge pricing and volumes. R&D spend remained focused on high-growth areas such as complex generics, biosimilars, peptides and novel biologics. <\/p>\n\n\n\n

Investor Reaction and Outlook<\/strong><\/h2>\n\n\n\n

Shares of Dr. Reddy\u2019s dipped in early trading following the results, reflecting investor caution over margin compression and slower profit growth despite the top-line beat. Analysts have pointed to the company\u2019s substantial exposure to the North American market, where generic pricing pressures and product mix shifts have weighed on recent earnings trends. <\/p>\n\n\n\n

Looking ahead, the company reiterated its commitment to balancing near-term profitability with long-term investments in innovation and geographic diversification, as it navigates a challenging global pharmaceutical landscape.<\/p>\n\n\n\n

Reasons to Pass on DRREDDY<\/strong><\/h2>\n\n\n\n
    \n
  • Declining Net Profit: Net profit fell 14% YoY to \u20b91,209.8 crore, signalling profitability erosion amid headwinds.<\/li>\n\n\n\n
  • Margin Compression: EBITDA margin contracted to 23.5% from 27.5%; gross margin eased to 53.6% from 58.7%, driven by pricing pressures and costs.<\/li>\n\n\n\n
  • North America Generics Weakness: Key revenue segment saw YoY decline due to lower lenalidomide and other product sales, offsetting gains elsewhere.<\/li>\n\n\n\n
  • One-Time Costs: Provisions for new labour code compliance in India added to expenses, hurting adjusted margins.<\/li>\n\n\n\n
  • Rising Expenses: SG&A increased from commercial investments; R&D at 7% of revenues reflects ongoing high spend without immediate returns.<\/li>\n\n\n\n
  • Investor Caution: Shares dipped post-earnings, highlighting concerns over U.S. exposure, pricing dynamics, and slower profit growth despite revenue beat.<\/li>\n\n\n\n
  • PSAI Segment Decline: Slight sales drop due to API market volatility, adding to overall revenue moderation.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    Dr. Reddy\u2019s Laboratories Ltd. (NSE: DRREDDY), the Indian drugmaker, on Wednesday reported a modest rise in third-quarter revenue but a notable decline in net profit as pressure from pricing and product-specific challenges weighed on earnings for the quarter ended Dec. 31, 2025.\u00a0 Revenue Growth Moderates; Profit Falls Consolidated revenue increased 4.4% year-on-year to \u20b98,726.8 crore […]<\/p>\n","protected":false},"author":2387,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392],"tags":[3187,8157,12577,10162],"class_list":["post-177061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","tag-biotechnology","tag-healthcare","tag-lifescience","tag-pharmaceutical"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":135275,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-limited-q2fy23-net-profit-increased-by-12\/","url_meta":{"origin":177061,"position":0},"title":"Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%","author":"Hardik Bhandare","date":"October 31, 2022","format":false,"excerpt":"Dr. Reddy's Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of \u20b963,318 Crore up from \u20b957,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to \u20b956,009 Crore. Consolidated Net Profit of \u20b911,142 up 12% from \u20b99,958 Crore in the same quarter\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":126133,"url":"https:\/\/alphastreet.com\/india\/infographic-all-you-need-to-know-about-dr-reddys-labs-q2-performance\/","url_meta":{"origin":177061,"position":1},"title":"Infographic: All you need to know about Dr Reddy’s Labs Q2 performance","author":"Nishad","date":"December 14, 2021","format":false,"excerpt":"Dr. Reddy's Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of \u20b95,992 crores with a growth of 20 % year on year. Dr Reddy's lab had a net profit of \u20b9964 crores or \u20b959.88 per share compared to \u20b9781 crores or \u20b946.40 per share\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/Dr.-Reddys-LaboratoriesQ222.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/Dr.-Reddys-LaboratoriesQ222.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/Dr.-Reddys-LaboratoriesQ222.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/Dr.-Reddys-LaboratoriesQ222.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/12\/Dr.-Reddys-LaboratoriesQ222.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":168307,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q4fy25-22-rise-in-profits\/","url_meta":{"origin":177061,"position":2},"title":"Dr. Reddy’s Laboratories Ltd Q4FY25; 22% rise in Profits","author":"Divyansh_Kasana","date":"May 9, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy's Laboratories reported Total revenue for Q4FY25 of \u20b9 9,050 Crore up from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145695,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-q4-fy23-net-profit-surged-up-to-%e2%82%b9960-crore\/","url_meta":{"origin":177061,"position":3},"title":"Dr Reddy’s Laboratories Q4 FY23; Net Profit Surged Up To \u20b9960 Crore","author":"Hardik Bhandare","date":"May 10, 2023","format":false,"excerpt":"Dr. Reddy\u2019s Laboratories Limited reported Total Income for Q4 FY23 of \u20b96,453.7 Crore up from \u20b95,596.8 Crore year on year, a growth of 15.3%. Consolidated Net Profit of \u20b9960.1 Crore, surged from \u20b997 Crore in the same quarter of the previous year. The Earnings per Share is \u20b957.68, from \u20b95.83\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/69a8bb46-8f0d-4225-ab06-f2f943aaae93.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":158686,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q3fy24-11-rise-in-profits\/","url_meta":{"origin":177061,"position":4},"title":"Dr Reddy’s Laboratories Ltd Q3FY24; 11% rise in Profits","author":"Divyansh_Kasana","date":"February 13, 2024","format":false,"excerpt":"Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr Reddy's Laboratories Ltd reported Revenues for Q3FY24 of \u20b97,237.00 Crores up from \u20b96,790.00 Crore year\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-99.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":125277,"url":"https:\/\/alphastreet.com\/india\/key-highlights-from-dr-reddys-q2-2022-earnings-results\/","url_meta":{"origin":177061,"position":5},"title":"Key highlights from Dr Reddy\u2019s Q2 2022 earnings results","author":"Nishadkishore","date":"October 29, 2021","format":false,"excerpt":"Dr Reddy\u2019s Laboratories (NSE: DRREDDY) reported its second-quarter financial results for the period ended September 30, 2021. The company had total revenue of \u20b957.6 billion with a growth of 18% year on year. Dr Reddy's reported a net profit of \u20b99.92 billion or \u20b959.65 per share compared to \u20b97.62 billion\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2387"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=177061"}],"version-history":[{"count":4,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177061\/revisions"}],"predecessor-version":[{"id":177065,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/177061\/revisions\/177065"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=177061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=177061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=177061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}